Compare Campbell Soup Co. (CPB) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Incyte Corporation — how do they compare? Campbell Soup Co. trades at $22.55 (market cap $6.78B), while Incyte Corporation trades at $121.08 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 3.6× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays a 6.87% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CPB | INCY | |
|---|---|---|
Market Cap | $6.78B | $24.54B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $129.93 |
52-Week Low | $20.00 | $81.61 |
Enterprise Value | $13.38B | $20.04B |
Dividend Yield | 6.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.42, down 2.73% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of $0.50, beating expectations of $0.4789, while Q4 2025 missed estimates. Revenue reached $10.25B in 2025 with a net income margin of 6.12%, though profitability metrics like ROE (3.09%) remain modest. Recent news highlights product innovation with new protein soups and leadership transitions aimed at business transformation.
The outlook for CPB is cautious with a consensus price target of $20.20 below the current price, reflecting analyst skepticism (58.62% Hold, 37.93% Sell). Opportunities include cost-saving initiatives and a sustainable ~7% dividend yield, but risks involve margin pressures, high debt levels, and competitive challenges in the packaged foods sector. Investors should weigh the dividend appeal against structural profitability concerns.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
